Loading
Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.
Helena A. Yu is a Medical Oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, specialising in EGFR-mutant lung cancer. She is known for mapping how EGFR-mutant lung cancers resist EGFR inhibitors such as osimertinib, including the T790M mutation and histological transformation, and for leading the HER3-directed antibody-drug conjugate trials that followed. Her selected papers analyse tumour specimens at the time of acquired resistance to EGFR inhibitors in 155 patients, and report HERTHENA-Lung01, a phase 2 trial of patritumab deruxtecan in EGFR-mutated lung cancer after prior therapy. She continues to study resistance mechanisms and ADCs in non-small-cell lung cancer.
| Title | Journal | Year |
|---|---|---|
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Clinical Cancer Research | 2013 |
| HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy | Journal of Clinical Oncology | 2023 |
Shares Patritumab deruxtecan, HER3, Non-small-cell lung cancer.
Shares Patritumab deruxtecan, Osimertinib, Non-small-cell lung cancer.
Shares Patritumab deruxtecan, HER3, Non-small-cell lung cancer.
Shares Patritumab deruxtecan, HER3.
Shares HER3, Non-small-cell lung cancer.
Shares Osimertinib, Non-small-cell lung cancer.